The National Cancer Institute, Division of Cancer Preventions Cancer Biomarkers Research Group has negotiated an Interagency Agreement with Department of Energy Pacific Northwest National Laboratory to provide for the development, production and dissemination of antibody microarray technologies, in stages 1 through 3 for the Cancer Early Detection Research Network (EDRN). PNNL has unique expertise in the field of molecularly engineered recombinant antibodies. The purpose of this project is to develop antibody microarrays through a contract mechanism with the PNNL. It is anticipated that this collaboration will permit the development, production and dissemination of antibody microarrays technologies for the Early Detection Research Network (EDRN) and research community of focusing on early detection, and risk assessment of cancer. A fully developed Antibody Microarrays Research Project (AMRP) may also serve as a protein array facility for clinical trials. The program may be an important new national resource and center for technology development and is utilized in clinical and preclinical studies. The specific objectives of the AMRP are: Stage 1: A feasibility study comparing limited number (~10) of available scFv library derived antibodies. Stage 2: Similar to phase 1 limited to ~50 antigens and controls. Stage 3: Generation of antibody microarrays for early detection ~ 400 selected markers and controls
